NVIDIA (NVDA) is considered a strong buy with a near-term price target of $200, fueled by massive, ongoing demand for its AI chips. For a long-term growth opportunity, Eli Lilly (LLY) is a top pick due to its leadership in the GLP-1 drug market and its disruptive direct-to-consumer strategy. On the bearish side, Joby Aviation (JOBY) is presented as a high-conviction short, with the view that the company may not exist in five years. The broader quantum computing sector, including D-Wave (QBTS), is also viewed as a speculative bubble ripe for short-selling. For a higher-risk, value-oriented play, consider Sarepta Therapeutics (SRPT), which is seen as undervalued with a potential price floor around $20 per share.

D-Wave Quantum (QBTS)

• The speaker has a strong bearish view on D-Wave, calling it a "monster's short".
• This short position is the speaker's biggest mistake this year, causing a significant drawdown in their portfolio. The speaker's average short price is around $5.
• Volatility Warning: Shorting this stock is described as jumping on a "roller coaster." Investors should be prepared for significant price swings and not expect it to drop immediately.
• Fundamental Concerns:
  • The speaker believes the company is part of a "quantum computing mini bubble."
  • They are skeptical of the technology, suggesting the company restricts access to its quantum computer because "their shit sucks" and they want to control the public narrative.
• The speaker continues to hold and add to their short position, viewing recent price fades as a positive sign.

Takeaways

• The sentiment is extremely bearish. The speaker is actively shorting the stock.
• This is a high-risk, high-volatility stock. Any position, long or short, will likely experience significant price swings.
• The core of the short thesis is a belief that the company's technology is overhyped and part of a speculative bubble.

Sarepta Therapeutics (SRPT)

• The speaker has a complex but ultimately bullish outlook on Sarepta, despite recent negative news and stock performance.
• They believe the company is facing regulatory issues with the FDA, which is "upset about this vector" used in their treatment, viewing it as dangerous.
• The speaker actively traded the stock, mentioning they sold at $28 and bought it back at $13.50, suggesting they see the recent drop as a buying opportunity.
• Valuation Floor: The speaker believes the stock has a floor and is undervalued.
  • They state the company's PMO (pre-market opportunity) business alone is worth $30 per share.
  • They "don't see how it could be under $20."
• They expect the current uncertainty ("the smoke") to clear and for the stock to be "fine." They also predict the current CEO, Doug, will be replaced soon.

Takeaways

• The overall sentiment is bullish, viewing the current low price as an attractive entry point based on the value of the company's existing assets.
• Investors should be aware of the significant regulatory risk from the FDA, which is the primary cause of the stock's recent decline.
• The speaker suggests a potential price floor around $20 and sees significant upside from current levels.

NVIDIA (NVDA)

• The speaker is extremely bullish on NVIDIA.
• They state, "I really like NVIDIA. That's going to be a $200 stock pretty quick."
• The primary reason for this bullishness is the massive, ongoing demand for its GPUs from major tech companies.
• They believe companies like Meta (META), OpenAI, and Microsoft (MSFT) "are never gonna stop buying" NVIDIA's chips.

Takeaways

• The sentiment is strongly bullish with a near-term price target of $200.
• The investment thesis is based on the continued, seemingly insatiable demand for AI hardware, with NVIDIA being the key supplier.

Joby Aviation (JOBY)

• The speaker has a very strong bearish view on Joby.
• They call it an "awesome short" and a "stupid company."
• The speaker makes a bold prediction: "Joby's not going to exist in five years."
• They confirm they are actively shorting the stock.

Takeaways

• The sentiment is extremely bearish.
• The speaker believes the company is fundamentally flawed and will ultimately fail, making it a prime short-selling candidate.

Eli Lilly (LLY)

• The speaker is bullish on Eli Lilly.
• They are optimistic about the growth of GLP-1 drugs (like Mounjaro) and see Lilly as the leader in this space.
• A key strategic advantage mentioned is the "Lilly direct" program, which they believe will disrupt competitors like Hims (HIMS) by selling directly to consumers.
• Being an American company is also seen as a positive factor.

Takeaways

• The sentiment is bullish, driven by Lilly's leadership in the high-growth GLP-1 market and its direct-to-consumer strategy.
• The success of "Lilly direct" could pose a significant threat to telehealth companies that act as intermediaries for these types of drugs.

Opendoor (OPEN)

• The speaker is neutral and cautious on Opendoor.
• They note its extremely high trading volume (93 million shares), making it the most active stock by a wide margin.
• The speaker finds the business model confusing and difficult to analyze without a deep dive into its financial reports (the 10-K).
• They state, "I wouldn't touch open door long or short for now" due to this lack of clarity.

Takeaways

• The speaker advises caution. The business is complex, and it's difficult to form a strong investment opinion without significant research.
• This is not a recommended long or short idea at this time.

Quantum Computing Sector

• The speaker believes the entire quantum computing sector is a "mini bubble."
• Many stocks in this sector, including IonQ (IONQ), Rigetti (RGTI), and Quantum Computing Inc. (QUBT), are viewed with skepticism.
• The speaker is shorting several of these names and was pleased to see them "giving back" their recent gains.
• IonQ (IONQ): The speaker is particularly skeptical of IonQ's technological claims, calling their modular design approach "wishful thinking" and their current devices "useless."

Takeaways

• The sector is viewed as highly speculative and overhyped.
• The speaker is broadly bearish on the sector and is shorting multiple companies within it, believing the bubble will eventually collapse.

Bitcoin (BTC) & Altcoins

• The speaker notes a Bitcoin price of 118K.
• They express skepticism about the idea that Bitcoin will "never again [go] below 100k."
• The speaker observes that "alt coins [are] out of control," which they interpret as a sign of extreme risk-taking in the market.
• This high "risk temperature" makes the speaker feel that "we're close to a top" in the broader market.

Takeaways

• The extreme rally in cryptocurrencies, particularly altcoins, is seen as a classic sign of market mania and a potential indicator of a looming market correction.
• While not giving a direct call on Bitcoin, the speaker seems to believe the current market environment is frothy and unsustainable.